A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency

Shadi Tabibian; Yavar Shiravand; Mahmood Shams; Majid Safa; Mohammad Saeed Gholami; Farshad Heydari; Abbas Ahmadi; Jamal Rashidpanah; Akbar Dorgalaleh

doi:10.1055/s-0039-1687906

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2019; 45(05): 523-543
DOI: 10.1055/s-0039-1687906

Review Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency

Shadi Tabibian

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

,

Yavar Shiravand

²Department of Hematology and Blood Transfusion, School of Allied Medicine, Tehran University of Medical Sciences, Tehran, Iran

,

Mahmood Shams

³Department of Medical Laboratory, Faculty of Paramedical Sciences, Babol University of Medical Sciences, Babol, Iran

,

Majid Safa

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

,

Mohammad Saeed Gholami

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

,

Farshad Heydari

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

,

Abbas Ahmadi

⁴Cellular and Molecular Research Center, Research Institute for Health Development, Department of Molecular Medicine and Genetics, Faculty of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran

,

Jamal Rashidpanah

⁵Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran

,

Akbar Dorgalaleh

¹Department of Hematology and Blood Transfusion, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

› Institutsangaben

Abstract

Coagulation factor (F) V is a glycoprotein that plays an essential role in the formation of the prothrombinase complex, which is critical for progressing clot formation. FV deficiency is a rare bleeding disorder with an estimated incidence of one per 1 million in the general population. The disorder is manifested with a wide array of clinical bleeding events. The most common bleeding features of FV deficiency are mucosal bleedings. Life-threatening manifestations are rarely seen in this disorder. FV deficiency is diagnosed using routine coagulation tests and FV activity assay. A wide spectrum of mutations including missense, nonsense, and frameshift is observed throughout the F5 gene. Although fresh frozen plasma is the dominant therapeutic choice, a newly introduced plasma-derived FV concentrate was found effective in in vitro correction of prothrombin time, activated partial thromboplastin time, and thrombin generation parameters in severe FV deficiency and should provide more targeted treatment for patients with FV deficiency in the future.

Keywords

factor V deficiency - molecular basis - clinical manifestations

Volltext

Referenzen

References
1 Tabibian S, Dorgalaleh A, Camire RM. Congenital Factor V Deficiency. Congenital Bleeding Disorders. New York, NY: Springer; 2018: 201-218
2 Mann KG, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood 2003; 101 (01) 20-30
3 Rosing J, Tans G, Govers-Riemslag JW, Zwaal RF, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255 (01) 274-283
4 Dorgalaleh A, Alavi SER, Tabibian S. , et al. Diagnosis, clinical manifestations and management of rare bleeding disorders in Iran. Hematology 2017; 22 (04) 224-230
5 Tabibian S, Kazemi A, Dorgalaleh A. Laboratory diagnosis of congenital factor V deficiency, routine, specific coagulation tests with molecular methods. J Cell Mol Anesth 2016; 1 (02) 87-90
6 Franchini M, Lippi G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 2011; 31 (04) 449-457
7 Lawrie AS, Berbenni C, Menegatti M. , et al. In vitro characterizations of the first therapeutic factor V concentrate. Haemophilia 2014; 20: 25-26
8 Duga S, Asselta R, Tenchini ML. Coagulation factor V. Int J Biochem Cell Biol 2004; 36 (08) 1393-1399
9 Orfeo T, Brufatto N, Nesheim ME, Xu H, Butenas S, Mann KG. The factor V activation paradox. J Biol Chem 2004; 279 (19) 19580-19591
10 Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007; 98 (03) 530-542
11 Hirbawi J, Vaughn JL, Bukys MA, Vos HL, Kalafatis M. Contribution of amino acid region 659-663 of factor Va heavy chain to the activity of factor Xa within prothrombinase. Biochemistry 2010; 49 (39) 8520-8534
12 Camire RM. A new look at blood coagulation factor V. Curr Opin Hematol 2011; 18 (05) 338-342
13 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31 (15) 3777-3785
14 Vadivel K, Kumar Y, Bunce MW, Camire RM, Bajaj MS, Bajaj SP. Interaction of factor V B-domain acidic region with its basic region and with TFPI/TFPI2: structural insights from molecular modeling studies. Int Biol Rev 2017 ;1(1)
15 Kim SW, Ortel TL, Quinn-Allen MA. , et al. Partial glycosylation at asparagine-2181 of the second C-type domain of human factor V modulates assembly of the prothrombinase complex. Biochemistry 1999; 38 (35) 11448-11454
16 Yang TL, Cui J, Rehumtulla A. , et al. The structure and function of murine factor V and its inactivation by protein C. Blood 1998; 91 (12) 4593-4599
17 Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood 2015; 125 (19) 2898-2907
18 Steen M. Factor Va-factor Xa interactions: molecular sites involved in enzyme: cofactor assembly. Scand J Clin Lab Invest Suppl 2002; 237 (07) 5-11
19 Nakayama D, Ben Ammar Y, Miyata T, Takeda S. Structural basis of coagulation factor V recognition for cleavage by RVV-V. FEBS Lett 2011; 585 (19) 3020-3025
20 Hockin M, Kalafatis M, Cawthern K, Simoni P, Mann K. , eds. A novel cellular mechanism for factor Va inactivation. 40th Annual Meeting of the American Society of Hematology Blood, Miami Beach, FL, December 1998
21 Kalafatis M, Mann KG. The role of the membrane in the inactivation of factor Va by plasmin. Amino acid region 307-348 of factor V plays a critical role in factor Va cofactor function. J Biol Chem 2001; 276 (21) 18614-18623
22 Pellequer J-L, Gale AJ, Getzoff ED, Griffin JH. Three-dimensional model of coagulation factor Va bound to activated protein C. Thromb Haemost 2000; 84 (05) 849-857
23 Nicolaes GA, Dahlbäck B. Factor V and thrombotic disease: description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22 (04) 530-538
24 Maas C, Meijers JC, Marquart JA. , et al. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma. Proc Natl Acad Sci U S A 2010; 107 (20) 9083-9087
25 Thomassen MC, Castoldi E, Tans G. , et al. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool. Haematologica 2003; 88 (10) 1150-1156
26 Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor: characterization of purified platelet-derived factor V/Va. J Biol Chem 2004; 279 (04) 2383-2393
27 Camire RM, Kalafatis M, Cushman M, Tracy RP, Mann KG, Tracy PB. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals. J Biol Chem 1995; 270 (35) 20794-20800
28 Diamandis M, Adam F, Kahr WH. , et al. Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis. J Thromb Haemost 2006; 4 (05) 1086-1094
29 Lippi G, Favaloro EJ, Montagnana M, Manzato F, Guidi GC, Franchini M. Inherited and acquired factor V deficiency. Blood Coagul Fibrinolysis 2011; 22 (03) 160-166
30 Duckers C, Simioni P, Spiezia L. , et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112 (09) 3615-3623
31 Thalji N, Camire RM. Parahemophilia: new insights into factor v deficiency. Semin Thromb Hemost 2013; 39 (06) 607-612
32 Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG. Factor VNew Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. Blood 1995; 86 (05) 1820-1827
33 Naderi M, Tabibian S, Hosseini MS. , et al. Rare bleeding disorders: a narrative review of epidemiology, molecular and clinical presentations, diagnosis and treatment. J Pediatr Rev 2014; 2 (02) 31-46
34 Naderi M, Tabibian S, Alizadeh S. , et al. Congenital factor V deficiency: comparison of the severity of clinical presentations among patients with rare bleeding disorders. Acta Haematol 2015; 133 (02) 148-154
35 Alavi SER, Jalalvand M, Assadollahi V, Tabibian S, Dorgalaleh A. Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders-prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency. Semin Thromb Hemost 2018; 44 (03) 267-275
36 Naderi M, Tabibian S, Shamsizadeh M, Dorgalaleh A. Miscarriage and recurrent miscarriage in patients with congenital factor V deficiency: a report of six cases in Iran. Int J Hematol 2016; 103 (06) 673-675
37 Tabibian S, Motlagh H, Naderi M, Dorgalaleh A. Intracranial hemorrhage in congenital bleeding disorders. Blood Coagul Fibrinolysis 2018; 29 (01) 1-11
38 Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost 2011; 37 (06) 713-720
39 Hayward CP, Liang M, Tasneem S. , et al. The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes. PLoS One 2017; 12 (03) e0173991
40 Hayward CP, Rivard GE. Quebec platelet disorder. Expert Rev Hematol 2011; 4 (02) 137-141
41 Stormorken H. The discovery of factor V: a tricky clotting factor. J Thromb Haemost 2003; 1 (02) 206-213
42 Caudill JS, Sood R, Zehnder JL, Pruthi RK, Steensma DP. Severe coagulation factor V deficiency associated with an interstitial deletion of chromosome 1q. J Thromb Haemost 2007; 5 (03) 626-628
43 Guella I, Paraboschi EM, van Schalkwyk WA, Asselta R, Duga S. Identification of the first Alu-mediated large deletion involving the F5 gene in a compound heterozygous patient with severe factor V deficiency. Thromb Haemost 2011; 106 (02) 296-303
44 Nuzzo F, Bulato C, Nielsen BI. , et al. Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency. Haemophilia 2015; 21 (02) 241-248
45 Frischmeyer PA, Dietz HC. Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet 1999; 8 (10) 1893-1900
46 Kalafatis M, Simioni P, Tormene D, Beck DO, Luni S, Girolami A. Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood 2002; 99 (11) 3985-3992
47 Ang AL, Kuperan P, Ng CH, Ng HJ. Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 2009; 101 (05) 852-859
48 Knöbl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11 (02) 305-318
49 Miesbach W, Voigt J, Peetz D, Scharrer I. Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin [in German]. Med Klin (Munich) 2003; 98 (06) 339-343
50 Lucia JF, Aguilar C. A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia 2005; 11 (02) 178-180
51 Takahashi H, Fuse I, Abe T, Yoshino N, Aizawa Y. Acquired factor V inhibitor complicated by Hashimoto's thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis 2003; 14 (01) 87-93
52 Emori Y, Sakugawa M, Niiya K. , et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 2002; 13 (06) 555-559
53 Koyama T, Saito T, Kusano T, Hirosawa S. Factor V inhibitor associated with Sjögren's syndrome. Br J Haematol 1995; 89 (04) 893-896
54 Wiwanitkit V. Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases. Clin Appl Thromb Hemost 2006; 12 (04) 485-488
55 Bowman LJ, Anderson CD, Chapman WC. Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost 2010; 36 (05) 477-484
56 Tilley D, Levit I, Samis JA. Measurement of factor v activity in human plasma using a microplate coagulation assay. J Vis Exp 2012; (67) 1-7
57 Tilley D, Levit I, Samis JA. Development of a microplate coagulation assay for Factor V in human plasma. Thromb J 2011; 9 (01) 11
58 Dacie JV. Dacie and Lewis Practical Haematology. Amsterdam: Elsevier Health Sciences; 2006
59 Favaloro EJ, Bonar R, Duncan E. , et al; RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006; 96 (01) 73-78
60 Favaloro EJ, Bonar R, Duncan E. , et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39 (05) 504-511
61 Kershaw G. Performance and interpretation of mixing tests in coagulation. Methods Mol Biol 2017; 1646: 85-90
62 Kadohira Y, Yamada S, Hayashi T, Morishita E, Asakura H, Ichinose A. A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors. Int J Hematol 2018; 108 (02) 145-150
63 Kershaw G. Detection and measurement of factor inhibitors. Methods Mol Biol 2017; 1646: 295-304
64 Favaloro EJ, Posen J, Ramakrishna R. , et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 2004; 15 (08) 637-647
65 Peyvandi F, Menegatti M. Treatment of rare factor deficiencies in 2016. Hematology (Am Soc Hematol Educ Program) 2016; 2016 (01) 663-669
66 Delev D, Pavlova A, Heinz S, Seifried E, Oldenburg J. Factor 5 mutation profile in German patients with homozygous and heterozygous factor V deficiency. Haemophilia 2009; 15 (05) 1143-1153
67 Acharya SS, Coughlin A, Dimichele DM. ; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004; 2 (02) 248-256
68 Mansouritorghabeh H, Manavifar L, Mobalegh A, Shirdel A. Haemorrhagic manifestations and prevalence of factor V deficiency in north-eastern Iran. Haemophilia 2010; 16 (02) 376-380
69 Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103 (04) 1067-1069
70 Cutler JA, Patel R, Rangarajan S, Tait RC, Mitchell MJ. Molecular characterization of 11 novel mutations in patients with heterozygous and homozygous FV deficiency. Haemophilia 2010; 16 (06) 937-942
71 Park C-H, Yoo K, Lee K-O, Kim S-H, Sung K-W, Kim H-J. Genetic confirmation of congenital factor V deficiency in Korean patients. Ann Lab Med 2016; 36 (02) 182-184
72 Huang DD, Wang XF, Chen HY. , et al. Analysis of phenotype and genotype in four Chinese pedigrees with inherited coagulation factor V deficiency [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2010; 31 (03) 149-153
73 Cao L, Wang Z, Li H. , et al. Gene analysis and prenatal diagnosis for two families of congenital factor V deficiency. Haemophilia 2011; 17 (01) 65-69
74 Kanaji S, Kanaji T, Honda M. , et al. Identification of four novel mutations in F5 associated with congenital factor V deficiency. Int J Hematol 2009; 89 (01) 71-75
75 Chen T-Y, Lin T-M, Chen H-Y, Wu C-L, Tsao C-J. Gly392Cys missense mutation in the A2 domain of factor V causing severe factor V deficiency: molecular characterization by expression of the recombinant protein. Thromb Haemost 2005; 93 (03) 614-615
76 Kovács KB, Tisza B, Komáromi I, Muszbek L, Bereczky Z. Inherited factor V deficiency associated with a novel heterozygous missense mutation (p.G493R) in a patient with excessive surgical bleeding. Thromb Haemost 2009; 102 (04) 787-789
77 Xie F, Cheng F, Zhu X. Studies on hereditary deficiency of coagulation factor V [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2001; 22 (09) 453-456
78 van Wijk R, Nieuwenhuis K, van den Berg M. , et al. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood 2001; 98 (02) 358-367
79 Lunghi B, Scanavini D, Castoldi E. , et al. The factor V Glu1608Lys mutation is recurrent in familial thrombophilia. J Thromb Haemost 2005; 3 (09) 2032-2038
80 Brugge JM, Simioni P, Bernardi F. , et al. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. J Thromb Haemost 2005; 3 (12) 2695-2702
81 Calzavarini S, Villoutreix BO, Lunghi B, Livaja R, Bernardi F, Dahlbäck B. Molecular basis of coagulation factor V deficiency caused by the R1698W inter-domain mutation. Thromb Haemost 2013; 110 (01) 31-38
82 Castoldi E, Simioni P, Kalafatis M. , et al. Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood 2000; 96 (04) 1443-1448
83 Montefusco MC, Duga S, Asselta R. , et al. Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. Blood 2003; 102 (09) 3210-3216
84 Wang X, Tang N, Lu Y, Li D. Congenital factor V deficiency and decreased VWF in a Chinese male patient with hematuria. Haemophilia 2018; 24 (01) e16-e18
85 Shinozawa K, Amano K, Suzuki T. , et al. Molecular characterization of 3 factor V mutations, R2174L, V1813M, and a 5-bp deletion, that cause factor V deficiency. Int J Hematol 2007; 86 (05) 407-413
86 Fu WJ, Hou J, Wang DX, Yu RQ. Identification of a novel mutation of human blood coagulation FV gene associated with congenital FV deficiency [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2003; 24 (03) 119-121
87 Asselta R, Bossone A, Iannaccone L, Duga S, Brancaccio V, Margaglione M. Rescue of activated protein C-resistance phenotype by cis-acting factor V Gly2032Asp mutation. Haematologica 2004; 89 (06) 761-762
88 Asselta R, Tenchini ML, Holme R, Brosstad F, Stormorken H. The discovery of Mary's mutation. J Thromb Haemost 2003; 1 (02) 397-398
89 Duga S, Montefusco MC, Asselta R. , et al. Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. Blood 2003; 101 (01) 173-177
90 Bossone A, D'Angelo F, Santacroce R, De Lucia D, Margaglione M. Factor V Arg2074Cys: a novel missense mutation in the C2 domain of factor V. Thromb Haemost 2002; 87 (05) 923-924
91 Schrijver I, Houissa-Kastally R, Jones CD, Garcia KC, Zehnder JL. Novel factor V C2-domain mutation (R2074H) in two families with factor V deficiency and bleeding. Thromb Haemost 2002; 87 (02) 294-299
92 Jin P-P, Wang X-F, Ding Q-L. , et al. Ser234Leu missense mutation in the A1 domain of factor V causing moderate factor V deficiency in a Chinese family. Pathology 2009; 41 (06) 566-571
93 Liu H-C, Lin T-M, Eng H-L, Lin Y-T, Shen M-C. Functional characterization of a novel missense mutation, His147Arg, in A1 domain of FV protein causing type II deficiency. Thromb Res 2014; 134 (01) 153-159
94 Janicki PK, Vaida S, Al-Mondhiry HA. Targeted next-generation resequencing of f5 gene identifies novel multiple variants pattern in severe hereditary factor v deficiency. Case Rep Genet 2013; 2013: 941684
95 Mumford AD, McVey JH, Morse CV. , et al. Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C. Br J Haematol 2003; 123 (03) 496-501
96 Lunghi B, Castoldi E, Mingozzi F, Bernardi F, Castaman G. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject. Blood 1998; 92 (04) 1463-1464
97 Vellinga S, Steel E, Vangenechten I, Gadisseur A. Successful pregnancy in a patient with factor V deficiency: case report and review of the literature. Thromb Haemost 2006; 95 (05) 896-897
98 Schrijver I, Hong DW, Mandle L. , et al. High frequency of premature termination mutations in the factor V gene: three factor V deficiency case reports and a mutation review. Thromb Haemost 2005; 93 (03) 610-611
99 van Wijk R, Montefusco MC, Duga S. , et al. Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency. Br J Haematol 2001; 114 (04) 871-874
100 Traynis I, Jones CD, Gibb CB, Acharya SS, Zehnder JL. First molecular characterization of a patient with combined factor V and factor VII deficiency. Thromb Haemost 2006; 95 (06) 1031-1032
101 Hou LH, Xie F, Liu XE. , et al. A novel mutation causes congenital factor V deficiency [in Chinese]. Zhonghua Xue Ye Xue Za Zhi 2003; 24 (09) 455-459
102 Nuzzo F, Paraboschi EM, Straniero L, Pavlova A, Duga S, Castoldi E. Identification of a novel large deletion in a patient with severe factor V deficiency using an in-house F5 MLPA assay. Haemophilia 2015; 21 (01) 140-147
103 Asselta R, Dall'Osso C, Duga S, Spreafico M, Saxena R, Tenchini ML. Coagulation factor V gene analysis in five Indian patients: identification of three novel small deletions. Haematologica 2006; 91 (12) 1724-1726
104 Montefusco MC, Duga S, Asselta R. , et al. A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. Br J Haematol 2000; 111 (04) 1240-1246
105 Zehnder JL, Hiraki DD, Jones CD, Gross N, Grumet FC. Familial coagulation factor V deficiency caused by a novel 4 base pair insertion in the factor V gene: factor V Stanford. Thromb Haemost 1999; 82 (03) 1097-1099
106 Montefusco MC, Asselta R, van Wijk R, Duga S, Tenchini ML. Concerns about the mutations identified in a case of familial coagulation factor V deficiency: factor V Stanford. Thromb Haemost 2000; 84 (06) 1131-1132
107 Castoldi E, Kalafatis M, Lunghi B. , et al. Molecular bases of pseudo-homozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998; 80 (03) 403-406
108 Guasch JF, Cannegieter S, Reitsma PH, van't Veer-Korthof ET, Bertina RM. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 1998; 101 (01) 32-39
109 Dargaud Y, Trzeciak MC, Meunier S. , et al. Two novel factor V null mutations associated with activated protein C resistance phenotype/genotype discrepancy. Br J Haematol 2003; 123 (02) 342-345
110 Ajzner E E, Balogh I, Szabó T, Marosi A, Haramura G, Muszbek L. Severe coagulation factor V deficiency caused by 2 novel frameshift mutations: 2952delT in exon 13 and 5493insG in exon 16 of factor 5 gene. Blood 2002; 99 (02) 702-705
111 DesPain AW, Kshetrapal A, Kousa YA. , et al. Management of intracranial hemorrhage in severe factor V deficiency and definitive treatment with liver transplantation. Pediatr Transplant 2018; 22 (01) e13102
112 Nuzzo F, Beshlawi I, Wali Y, Castoldi E. High incidence of intracranial bleeding in factor V-deficient patients with homozygous F5 splicing mutations. Br J Haematol 2017; 179 (01) 163-166
113 Fu QH, Zhou RF, Liu LG. , et al. Identification of three F5 gene mutations associated with inherited coagulation factor V deficiency in two Chinese pedigrees. Haemophilia 2004; 10 (03) 264-270
114 Dall'Osso C, Guella I, Duga S. , et al. Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern. Haematologica 2008; 93 (10) 1505-1513
115 Castoldi E, Duckers C, Radu C. , et al. Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma. J Thromb Haemost 2011; 9 (05) 959-968
116 Lunghi B, Pinotti M, Maestri I, Batorova A, Bernardi F. Evaluation of factor V mRNA to define the residual factor V expression levels in severe factor V deficiency. Haematologica 2008; 93 (03) 477-478
117 Schrijver I, Koerper MA, Jones CD, Zehnder JL. Homozygous factor V splice site mutation associated with severe factor V deficiency. Blood 2002; 99 (08) 3063-3065
118 Asselta R, Montefusco MC, Duga S. , et al. Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain. J Thromb Haemost 2003; 1 (06) 1237-1244
119 Jones CD, Yeung C, Negro F, Zehnder JL. Molecular characterization and subcellular localization of Tyr478del: a pathogenic in-frame deletion in coagulation factor V. J Thromb Haemost 2007; 5 (02) 431-433
120 Paraboschi EM, Kayiran SM, Özbek N. , et al. Functional characterization of a novel missense mutation identified in a Turkish patient affected by severe coagulation factor V deficiency. Haemophilia 2012; 18 (02) 205-210
121 Kling SJ, Griffee M, Flanders MM, Rodgers GM. Factor V deficiency caused by a novel missense mutation, Ile417Thr, in the A2 domain. J Thromb Haemost 2006; 4 (02) 481-483
122 Yamakage N, Ikejiri M, Okumura K. , et al. A case of coagulation factor V deficiency caused by compound heterozygous mutations in the factor V gene. Haemophilia 2006; 12 (02) 172-178
123 Cai X-H, Wang X-F, Ding Q-L, Fu Q-H, Wang H-L. Factor V C1149G and 5609-10INSCGTGGTT causing factor V deficiency: molecular characterization by in-vitro expression. Thromb Haemost 2007; 98 (03) 683-685
124 Fu Q, Wu W, Ding Q. , et al. Type I coagulation factor V deficiency caused by compound heterozygous mutation of F5 gene. Haemophilia 2003; 9 (05) 646-649
125 Zheng W, Liu Y, Luo Y. , et al. Molecular characterisation of Tyr530Ser and IVS16-1G>T mutations causing severe factor V deficiency. Thromb Haemost 2010; 104 (03) 536-543
126 Wang Y, Zhu L, Ye L, Xie Y, Pan J, Wang M. Factor V deficiency caused by a novel nonsense mutation (Gln2031stop) in a Chinese patient. Blood Coagul Fibrinolysis 2014; 25 (03) 283-285
127 Song J, Guella I, Kwon K-Y. , et al. A novel in-frame deletion in the factor V C1 domain associated with severe coagulation factor V deficiency in a Korean family. Blood Coagul Fibrinolysis 2009; 20 (02) 150-156
128 Coppola A, Maruotti GM, Feola G. , et al. Management of patients with factor V deficiency: open issues from the challenging history of a woman with anaphylactic transfusion reactions. Haemophilia 2010; 16 (03) 560-563
129 Bafunno V, Favuzzi G, Fierro T. , et al. Coinheritance of three novel FV gene mutations in a patient with a severe FV deficiency. Haemophilia 2012; 18 (02) e51-e53
130 Borhany M, Ranc A, Fretigny M, Moulis G, Abid M, Shamsi T. , et al. Molecular analysis of eight severe FV-deficient patients in Pakistan: A large series of homozygous for frameshift mutations. Haemophilia 2019 . doi: 10.1111/hae.13741. [Epub ahead of print]
131 Paraboschi EM, Menegatti M, Peyvandi F, Duga S, Asselta R. Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency. Int J Mol Sci 2019; 20 (04) 910